
Sign up to save your podcasts
Or
In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.
Featured Articles
4.1
4848 ratings
In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.
Featured Articles
133 Listeners
315 Listeners
26 Listeners
488 Listeners
91 Listeners
1,110 Listeners
3 Listeners
191 Listeners
349 Listeners
1 Listeners
1 Listeners
28 Listeners
169 Listeners
49 Listeners
3 Listeners